Marine fish-derived bioactive peptides as potential antihypertensive agents

Hypertension remains a leading risk factor for cardiovascular diseases globally. Current treatments often involve angiotensin-converting enzyme (ACE) inhibitors, which reduce vasoconstriction by blocking angiotensin II formation. Prior research has shown that ACE inhibition is a validated approach for managing high blood pressure. However, synthetic drugs may have side effects, prompting interest in natural alternatives. Marine sources have been explored for bioactive compounds, but specific antihypertensive peptides remain understudied. This gap motivated the investigation into marine-derived peptides. No prior work had resolved the full potential of these peptides in functional food applications. Understanding their mechanism could expand therapeutic options.

This study aimed to evaluate marine fish-derived peptides as antihypertensive agents. The specific problem addressed is the need for natural ACE inhibitors with fewer side effects. Researchers focused on peptides extracted from muscle proteins, skin collagen, and gelatin of various marine species. The motivation stems from the growing interest in functional foods and nutraceuticals. By isolating and characterizing these peptides, the study sought to establish their relevance in hypertension management. The goal was to determine whether these peptides could serve as viable alternatives to synthetic drugs. Their potential for application in food products was also considered. This approach aligns with broader efforts to harness marine biodiversity for health benefits.

The study employed enzymatic hydrolysis to extract peptides from marine fish tissues. Proteins from muscle, skin collagen, and gelatin were the primary sources. Enzymatic digestion was used to break down complex proteins into smaller peptides. The resulting mixtures were analyzed for ACE inhibitory activity. Researchers used chromatographic techniques to isolate and purify active peptides. In vitro assays measured ACE inhibition levels quantitatively. Comparative analysis was conducted to assess the potency of different peptides. The methods focused on identifying peptides with high inhibitory potential for further development.

Several marine-derived peptides showed strong ACE inhibitory activity. The most effective peptides were isolated from muscle proteins and gelatin sources. Inhibitory activity was measured using in vitro assays, with some peptides reaching over 90% inhibition. These findings suggest that marine fish peptides may function as antihypertensive agents. The study reported that specific amino acid sequences were associated with higher inhibitory effects. No significant differences were observed between collagen and gelatin-derived peptides. The results indicate that these peptides could be developed into functional food components. Further research is needed to confirm their efficacy in vivo.

The authors propose that marine fish-derived peptides may serve as antihypertensive components in functional foods. The study highlights the potential of these peptides as natural ACE inhibitors. Their findings suggest that these peptides could be used in nutraceutical applications. The researchers emphasize the need for further in vivo studies to validate these effects. The study does not claim that these peptides are essential for treating hypertension. Instead, it suggests they may complement existing therapies. The authors also note that marine sources offer a sustainable option for peptide extraction. The implications focus on expanding the range of available antihypertensive treatments.